Monsanto (MON) Cuts FY15 EPS Outlook into BofA Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
Despite Moderating Near-Term Outlook, Strength of Core Business, New Platforms and Financial Discipline Continue to Back Confidence in Long-Term Growth Opportunity for Monsanto
March 2, 2016 8:00 AM ESTNear term, with deteriorating macro environment, company revises full-year ongoing EPS guidance to $4.40 to $5.10; full year as-reported guidance to $3.42 to $4.29 Beyond FY16, key variables and growth drivers reinforce outlook and opportunity for a baseline mid-teens compounded annual growth rate in its ongoing EPS from the mid-point of its FY16 outlook through FY19 With continued strong grower demand, Intacta RR2 PROTM soybeans tracking to 35 million acres across South America; Initial shipments of Roundup Ready 2 XtendTM soybeans underway following China import approval with strong grower demand,... More
